Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirabegron + Solifenacin succinate - Astellas Pharma

Next Previous
Drug Profile

Mirabegron + Solifenacin succinate - Astellas Pharma

Alternative Names: EB 178; Solifenacin/mirabegron; YM178/YM905

Latest Information Update: 02 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma Europe Ltd
  • Class Acetamides; Antispasmodics; Esters; Ethanolamines; Isoquinolines; Quinuclidines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Overactive bladder
  • Phase III Bladder dysfunction

Most Recent Events

  • 01 Oct 2021 Phase-III clinical trials in Bladder dysfunction (In adolescents, In children, In infants, In neonates) in Europe, prior to October 2021 (PO) (Astellas Pharma pipeline, October 2021)
  • 01 Oct 2021 Phase-III clinical trials in Overactive bladder (In adolescents, In children, In infants, In neonates) in Europe, prior to October 2021 (PO) (Astellas Pharma pipeline, October 2021)
  • 28 Sep 2021 Discontinued - Phase-III for Overactive bladder in Israel, Ireland, Greece, Hungary, France, Georgia, Germany, Denmark, Finland, Austria, Argentina, Armenia, Colombia, United Kingdom, Sweden, Switzerland, Spain, Taiwan, Poland, Peru, Portugal, Netherlands, Lebanon, Norway, Slovakia, Slovenia, Romania, Mexico (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top